A detailed history of Black Rock Inc. transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,368,451 shares of LBPH stock, worth $142 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,368,451
Previous 1,866,290 26.91%
Holding current value
$142 Million
Previous $40.3 Million 58.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$17.0 - $27.03 $8.54 Million - $13.6 Million
502,161 Added 26.91%
2,368,451 $64 Million
Q1 2024

May 10, 2024

BUY
$18.89 - $26.06 $18.8 Million - $26 Million
996,411 Added 114.55%
1,866,290 $40.3 Million
Q4 2023

Feb 13, 2024

BUY
$3.68 - $6.5 $309,278 - $546,279
84,043 Added 10.69%
869,879 $5.25 Million
Q3 2023

Nov 13, 2023

BUY
$5.49 - $7.49 $248,329 - $338,795
45,233 Added 6.11%
785,836 $4.37 Million
Q2 2023

Aug 11, 2023

BUY
$4.19 - $10.05 $2.98 Million - $7.15 Million
711,581 Added 2451.87%
740,603 $5.44 Million
Q1 2023

May 12, 2023

BUY
$3.84 - $5.96 $36,487 - $56,631
9,502 Added 48.68%
29,022 $116,000
Q4 2022

Feb 13, 2023

BUY
$2.95 - $5.5 $1,837 - $3,426
623 Added 3.3%
19,520 $63,000
Q3 2022

Nov 14, 2022

SELL
$2.95 - $4.7 $8,360 - $13,319
-2,834 Reduced 13.04%
18,897 $70,000
Q2 2022

Aug 12, 2022

SELL
$2.96 - $5.38 $26,456 - $48,086
-8,938 Reduced 29.14%
21,731 $67,000
Q1 2022

May 12, 2022

BUY
$4.0 - $6.0 $50,304 - $75,456
12,576 Added 69.51%
30,669 $164,000
Q4 2021

Feb 10, 2022

BUY
$4.75 - $9.45 $2,232 - $4,441
470 Added 2.67%
18,093 $89,000
Q3 2021

Nov 09, 2021

SELL
$8.65 - $11.36 $3,252 - $4,271
-376 Reduced 2.09%
17,623 $156,000
Q2 2021

Aug 11, 2021

BUY
$7.95 - $17.3 $143,092 - $311,382
17,999 New
17,999 $164,000

Others Institutions Holding LBPH

About Longboard Pharmaceuticals, Inc.


  • Ticker LBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,586,000
  • Market Cap $815M
  • Description
  • Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...
More about LBPH
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.